アムロジピン暴露における報告された用量と結果の関係: 25年後の毒中センターレビュー
Colleen P Cowdery1, Courtney Temple1
1Department of Emergency Medicine, Oregon Health & Science University, Portland, OR, USA.
Clinical toxicology (Philadelphia, Pa.)
|September 4, 2025
まとめ
高用量アムロディピン (カルシウムチャネルブロッカー) の中毒は重度のショックを引き起こす可能性があります. 400mg以上摂取すると 耐火性ショックのリスクが高まり,静脈動脈外膜酸素化などの高度な治療が必要になります.
科学分野:
- 毒理学について
- 心臓病科
- 臨床医学
背景:
- アムロジピン (dihydropyridine カルシウムチャネルブロッカー) は,致命的な中毒にますます関与しています.
- プラズマ濃度のピークが遅れた場合,最初の中毒の重さを隠すことができます.
- 臨床結果の予測には,アムロディピンの投与量による分層化が不可欠である.
研究 の 目的:
- 報告されたアムロジピン摂取量と臨床結果の相関性
- アムロジピンによる重度の毒性の値を特定する.
- 摂取量に基づいた高度な介入の必要性を評価する.
主な方法:
- オレゴン州毒物センターの 25年間の記録を振り返る
- 含有基準: アムロジピン暴露,報告された用量,心臓発作併用摂取なし,血管活性剤/ イノトロプ剤で治療.
- 静脈動脈外膜酸素化 (VA- ECMO) と死亡率との投与量反応の分析
主要な成果:
- 摂取量 ≤250mgの20例では血管圧縮薬の必要性が最小で,1例はVA- ECMOで死亡例はありませんでした.
- 401〜1000mgの摂取の14例は,86%が4つの血管圧縮薬,43%がVA- ECMO,そして29%の死亡率を示した.
- 701〜1000mgの摂取の7例は,すべて4つの血管圧縮剤を必要とし,57%がVA- ECMOを受け,生存しました.
結論:
- アムロジピンによる毒性は,耐火性血管麻痺のショックを引き起こす可能性があります.
- 摂取用量は,血管圧縮剤の必要量,VA- ECMOの使用量,および死亡率と相関しています.
- 摂取量 ≥400mgは,VA-ECMOを含む高度な治療の早期移転を正当化し,投与量はリスクの階層化ツールとして機能します.
関連する概念動画
Time Course of Drug Effect
2.2K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.2K
Pharmacovigilance
981
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
981
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
173
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
173
Drug Dosage Regimen: Overview
3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Dose-Response Relationship: Overview
3.6K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.6K
Dose-Response Relationship: Potency and Efficacy
5.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.1K


